Exclusive Summary

• · Recombinant fully human tumor necrosis factor-α monoclonal antibody, the "Global Drug King" biosimilar with many indications and large sales in the field of autoimmune diseases
• · A total of 648 patients were included in the phase III clinical study, which is a phase III clinical study with a relatively large sample size among similar products in China, and the efficacy and safety have been fully verified